作者
Sven C van Dijkman, Rob A Voskuyl, Elizabeth C de Lange
发表日期
2017/11/15
来源
European Journal of Pharmaceutical Sciences
卷号
109
页码范围
S47-S52
出版商
Elsevier
简介
Biomarkers can be categorised from type 0 (genotype or phenotype), through 6 (clinical scales), each level representing a part of the processes involved in the biological system and drug treatment. This classification facilitates the identification and connection of information required to fully (mathematically) model a disease and its treatment using integrated information from biomarkers. Two recent reviews thoroughly discussed the current status and development of biomarkers for epilepsy, but a path towards the integration of such biomarkers for the personalisation of anti-epileptic drug treatment is lacking. Here we aim to 1) briefly categorise the available epilepsy biomarkers and identify gaps, and 2) provide a modelling perspective on approaches to fill such gaps. There is mainly a lack of biomarker types 2 (target occupancy) and 3 (target activation). Current literature typically focuses on qualitative biomarkers for …
引用总数
20182019202020212022202320243111211
学术搜索中的文章
SC van Dijkman, RA Voskuyl, EC de Lange - European Journal of Pharmaceutical Sciences, 2017